Application of in vitro PAMPA technique and in silico computational methods for blood-brain barrier permeability prediction of novel CNS drug candidates.
Blood-brain barrier permeability
CNS drugs
PAMPA
QSPR
SMD
hDAT
Journal
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982
Informations de publication
Date de publication:
01 Jan 2022
01 Jan 2022
Historique:
received:
12
07
2021
revised:
09
10
2021
accepted:
31
10
2021
pubmed:
7
11
2021
medline:
17
12
2021
entrez:
6
11
2021
Statut:
ppublish
Résumé
Permeability assessment of small molecules through the blood-brain barrier (BBB) plays a significant role in the development of effective central nervous system (CNS) drug candidates. Since in vivo methods for BBB permeability estimation require a lot of time and resources, in silico and in vitro approaches are becoming increasingly popular nowadays for faster and more economical predictions in early phases of drug discovery. In this work, through application of in vitro parallel artificial membrane permeability assay (PAMPA-BBB) and in silico computational methods we aimed to examine the passive permeability of eighteen compounds, which affect serotonin and dopamine levels in the CNS. The data set was consisted of novel six human dopamine transporter (hDAT) substrates that were previously identified as the most promising lead compounds for further optimisation to achieve neuroprotective effect, twelve approved CNS drugs, and their related compounds. Firstly, PAMPA methods was used to experimentally determine effective BBB permeability (P
Identifiants
pubmed: 34740787
pii: S0928-0987(21)00358-4
doi: 10.1016/j.ejps.2021.106056
pii:
doi:
Substances chimiques
Central Nervous System Agents
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106056Informations de copyright
Copyright © 2021. Published by Elsevier B.V.